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Abstract
Background: To evaluate the safety, efficacy, refractive outcomes and causes for bilensectomy (phakic intraocular
lens – pIOL – explantation with cataract surgery and pseudophakic intraocular lens implantation) in patients
previously implanted with posterior chamber pIOLs.
Methods: This multi-center retrospective study included 87 eyes of 55 patients who underwent bilensectomy for
posterior chamber pIOL with a follow up time of 12 months. The uncorrected and best corrected distance visual
acuities (UDVA, CDVA), endothelial cell density before and after bilensectomy were assessed, as well as the cause of
bilensectomy and intra or postoperative complications.
Results: There was a statistically significant improvement in uncorrected and best corrected visual acuities after
bilensectomy (p = 0.00). The main reason for bilensectomy was cataract development (93.1% of the cases), followed
by miscalculation of lens size, and corneal edema. The endothelial cell count remained stable without a statistically
significant change after surgery (p = 0.67). The refractive efficacy index was 0.8, none of the patients lost lines of
CDVA after surgery, 73% of the patients were within ±1 D (spherical equivalent) of the target refraction.
Intraoperative complications were one posterior capsule rupture with the intraocular lens (IOL) implanted in the
sulcus, and 3 eyes required the use of pupil expanders for adequate pupil dilation. Postoperatively, one eye
developed retinal detachment. The three pIOLs models explanted were the Implantable Collamer Lens (ICL),
Implantable Phakic Contact Lens (IPCL) and the Phakic Refractive Lens (PRL).
Conclusions: Good safety and visual outcomes were observed 1 year after bilensectomy for posterior chamber
phakic intraocular lenses (PC pIOLs). There were few intra and postoperative complications and there was no
significant endothelial cell loss after the bilensectomy procedure.
Keywords: Bilensectomy, Posterior chamber phakic intraocular lenses, Cataract, Endothelial cell count, Visual
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Background
The correction of high ametropias with phakic intraocular
lenses (pIOL) has the advantage of excellent visual out-
comes, accommodation maintenance, and reversibility;
contrary to laser refractive surgery [1–4]. Posterior cham-
ber phakic intraocular lenses (PC pIOLs) are widely used,
and their implantation is relatively easy. Furthermore, they
have long-term predictable and stable results for the cor-
rection of myopia [1], hyperopia [2] and astigmatism [3,
4]. Nowadays, the commercially available PC pIOLs are
the Implantable Collamer Lens (Staar Surgical Co, Mon-
riva, California) and the Implantable Phakic Contact Lens
(IPCL, Care Group Sight solutions, India). Other PC
pIOLs like the phakic refractive lens (PRL, Zeiss Meditec,
Jena, Germany) were phased out from the market due to
associated long term complications [5].
In spite of all the possible advantages that a pIOL may
offer, all patients with a pIOL will eventually undergo
bilensectomy (pIOL explantation with cataract surgery
and posterior chamber intraocular lens – IOL – implant-
ation), either due to a pIOL-induced cataract or the devel-
opment of an age-related cataract. Many studies have
reported the causes and incidence of cataract after the im-
plantation of a PC pIOL [6–8], but few have really re-
ported the clinical outcomes after bilensectomy [9], with
only a few clinical cases available [10, 11]. The aim of this
study is to evaluate the safety, efficacy, refractive out-
comes, and indications for bilensectomy in patients with
posterior chamber pIOLs, with a minimum postoperative
follow up of 12months. To the best of our knowledge, this
is the only study that describes the outcomes of bilensect-
omy with different models of posterior chamber pIOLs.
Methods
This is a retrospective, multicenter study, involving 87
eyes that had bilensectomy after PC pIOL implantation.
All data was obtained from the IBERIA biobank.1 The
Spanish centers that participated in this study were: Vis-
sum Alicante (Alicante), and Vissum Madrid (Madrid),
Centro de Oftalmología Barraquer (Barcelona), and the
Instituto Catalán de Retina-ICR (Barcelona). This study
was approved by the local research ethics committees
and was performed in compliance with the principles of
the Declaration of Helsinki.
Indications for the implantation of PC pIOLs were the
following: ametropia that could not be corrected with
corneal laser refractive surgery (extremely high myopes
or patients with thin corneas), anterior chamber depth
greater than 2.8 mm, irido-corneal angle greater than
30°, endothelial cell count (ECC) > 2500 cells/mm2.
Indications for bilensectomy were the following: cata-
ract development with loss of two or more lines of cor-
rected distance visual acuity (CDVA) or ECC < 1200
cells/mm2.
Preoperative assessment included: uncorrected dis-
tance visual acuities (UDVA) and CDVA respectively
measured with ETDRS charts, slit lamp examination,
Goldmann applanation tonometry, fundus examination,
and central ECC measurements taken with a noncontact
specular microscope (Noncon Robo-CA, Konan). The
intraocular lens (IOL) to be implanted was calculated
preoperatively using interferometry (IOLMaster, Carl
Zeiss Meditec AG). The SRK-T formula with the Wang/
Koch adjustment was used and the target refraction was
emmetropia in all cases. Bilensectomy was performed by
four experienced surgeons (JLA, JIB, RIB, FD). A monofo-
cal or multifocal IOL was implanted depending on pa-
tients’ postoperative visual expectations, preoperative
ophthalmic examination, daily activities (intermediate and
near visual needs), and age. Toric IOLs were implanted in
those patients with a topographic astigmatism > 1.5 D.
The technique for pIOL removal was as follows: Two
1mm side ports were created, intracameral mydriatic
was used to dilate the pupil and dispersive viscoelastic
(Viscoat, Alcon) was injected to protect the corneal
endothelium. A 3.2 mm clear corneal incision was made.
The 4 footplates of the pIOL were carefully lifted into
the anterior chamber and carefully explanted through
the main incision. Coaxial phacoemulsification was per-
formed with implantation of a posterior chamber IOL. A
cohesive viscoelastic (Provisc, Alcon) was used to keep
the capsular bag open for IOL insertion. After injecting
intracameral antibiotic, the main incision and paracen-
tesis were hydrated and sealed (Additional file 1). Post-
operative medications included topical antibiotics for a
week and steroids tapered over 4 weeks.
The main outcome measures were: efficacy (UDVA
after bilensectomy / CDVA after bilensectomy), percent-
age of eyes in which the postoperative CDVA was worse
than the preoperative CDVA (safety), refractive predict-
ability and central ECC change. The secondary outcomes
were: bilensectomy etiology, and intra/postoperative
complications.
Statistical analysis
Statistical analysis was performed with the SPSS software
for Windows (version 15.0.1). The average values and
standard deviations were calculated for every parameter.
Normality of all data was evaluated by means of the
Kolmogorov-Smirnov test. When parametric analysis
was possible, the Student’s t test for paired data was per-
formed for all parameter comparison between preopera-
tive and postoperative examinations. When parametric
analysis was not possible, the Wilcoxon test was applied
1IBERIA Biobank is a Collection of Intraocular Lenses and Other
Ocular Explanted Devices in Spain and Portugal.
Vargas et al. Eye and Vision            (2020) 7:34 Page 2 of 8
to assess the significance of differences between pre-
operative and postoperative data. For all statistical tests
a p value less than 0.05 was considered statistically
significant.
Results
The mean follow up time after bilensectomy was
14.5 ± 5.6months. The mean age at bilensectomy was
44.4 ± 7.3 years. The most frequent cause for bilensectomy
was cataract development (84 eyes), followed by corneal
edema (1 eye), IOL dislocation (1 eye), refractive surprise
(1 eye). Anterior subcapsular opacification was the most
common type of cataract (43%) followed by the posterior
subcapsular opacification (Figs. 1 and 2). Of the three
models of pIOLs explanted, 72 were ICL (models V3 and
V4, and one V4c), 7 were IPCL and 8 were PRL. The
mean time between the pIOL implantation and bilensect-
omy was 85.2 ± 61.59months. Table 1 shows the mean
time between the implantation of each type of PC pIOL
model and their subsequent bilensectomy. The preopera-
tive and postoperative outcomes are presented in Table 2.
The mean preoperative and postoperative UDVA and
CDVA of each pIOL model are presented in Table 3.
Sixty-eight percent of the patients had an UCVA of 20/40
or better, and 86% had a CDVA of 20/40 or better (Fig. 3).
Thirty nine percent of the patients had the same uncor-
rected and corrected visual acuities postoperatively (Fig. 4).
None of the eyes had a postoperative CDVA worse than
the preoperative.
The efficacy index was 0.8 (mean UDVA postop/ mean
CDVA postop), 73% of the eyes were within ±1.00 D
(spherical equivalent) of the attempted correction (Fig. 5).
Regarding the refractive cylinder, 28.5% of the eyes had
a postoperative value < 0.5 D (Fig. 6). Endothelial cell
density did not significantly change after surgery (p =
0.67).
Two eyes required a combined bilensectomy with tra-
beculectomy, postoperatively the IOP was controlled
with a good final visual outcome (CDVA of 20/35). One
eye had a combined bilensectomy with pupilloplasty
with a final CDVA of 20/25, and one eye had a com-
bined bilensectomy with Descemet’s stripping automated
endothelial keratoplasty (DSAEK).
We had one case with pIOL (PRL) dislocation second-
ary to broken zonules, this patient did not present with
any intra or postoperative complications. His final
CDVA was 20/25.
Thirteen multifocal IOLs were implanted, all the
rest were monofocal IOLs. The multifocal IOLs
implanted were: Lentis Mplus LS 313 MF + 1.5D
and + 3.0D (Oculentis GmbH, Berlin, Germany), AT
Lisa tri 389 MP (Carl Zeiss Meditec, Henningsdorf,
Germany), FineVision (PhysIOL SA, Liège, Belgium),
ReSTOR AD1 (Alcon Lab, Fort Worth, Texas, USA),
Versario Multifocal 3F IOL (Valeant Med Sp.zo.o.,
Warsaw, Poland) and AcriLISA 366D Carl Zeiss Med-
itec, Jena, Germany).
The visual outcome of these patients was good with a
mean UDVA of 20/35, CDVA of 20/25 and an efficacy
index of 0.8. Forty six percent of the patients implanted
with a multifocal IOL were younger than 45 years, none
of them had any postoperative optical complication.
Fig. 1 Percentage of the different types of cataracts presented in our study
Vargas et al. Eye and Vision            (2020) 7:34 Page 3 of 8
Intraoperative complications were as follows: one eye
had a posterior capsule rupture with the IOL implanted
in the sulcus, 3 eyes required the use of pupil expanders
for adequate pupil dilation.
Postoperative complications were as follows: as an
early complication, one eye had a retinal detachment
(RD) immediately after the surgery, eventually attaining
a final CDVA of 20/130 after pars plana vitrectomy, this
visual outcome was still better than the one he had be-
fore the bilensectomy (counting fingers).
As a late complication, four eyes presented with pos-
terior capsule opacification that was successfully treated
with neodymium-doped yttrium-aluminum-garnet (Nd:
YAG) laser capsulotomy.
Discussion
Refractive surgeons should consider the explantation of
all phakic IOLs at some point [12]; either due to the in-
cidence of cataract after the implantation of PC pIOLs
[13, 14] or the development of an age-related cataract, a
bilensectomy will be necessary in those patients, there-
fore it is important to report the long term outcomes of
such procedures.
We found a significant improvement in both UDVA
and CDVA after bilensectomy, with an acceptable effi-
cacy index and good safety that correlates to the findings
from other studies [9, 10]. Eighty six percent of our pa-
tients had a final CDVA of 20/40 or better. This appar-
ently limited visual outcome is influenced by the
concomitant retinal comorbidities of some of these high
myopic patients such as previous RD (one eye had a RD
one year after the implantation of the pIOL), foveoschi-
sis, and myopic chorioretinal atrophy - all complications
connected to high myopia [15].
Intra and postoperative complications were few, although
one of them was sight-threatening (RD) and directly con-
nected to the high myopia suffered by these patients.
Refractive outcomes were good, with a significant im-
provement in the sphere and spherical equivalent. The
SRK-T formula with the Wang/Koch adjustment had
good results, although nowadays the Barret Universal II
formula is more accurate for the IOL calculation in cases
Fig. 2 Type and percentage of cataracts developed by each phakic IOL model
Table 1 Time in months between phakic IOL implantation and
bilensectomy
Phakic IOL model Time
Mean ± SD
ICL 99.3 ± 43.7
IPCL 5.5 ± 2.7
PRL 67.1 ± 52.1
ICL= Implantable Collamer Lens, IPCL= Implantable Phakic Contact Lens, PRL=
Phakic Refractive Lens







UCVA (logMAR) 0.88 ± 0.63 0.31 ± 0.28 0.00
Sphere (D) −0.63 ± 2.6 0.66 ± 1.1 0.00
Cylinder (D) − 0.92 ± 1.08 −0.94 ± 0.84 0.71
Spherical equivalent (D) − 1.10 ± 2.5 0.20 ± 1.2 0.00
CDVA (logMAR) 0.43 ± 0.44 0.15 ± 0.19 0.00
Endothelial cell density
(cells/mm2)
2212 ± 667 2168 ± 618 0.67
SD= standard deviation, UCVA= uncorrected distance visual acuity, CDVA=
corrected distance visual acuity
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with extreme myopia (AL > 28mm) [16]. The different
methods that can be used for IOL calculation in the pres-
ence of a pIOL are: standard ultrasound biometry, intraop-
erative ultrasound biometry, intraoperative autorefraction
and partial coherence interferometry [17]. We used the lat-
ter as it provides adequate measurements in eyes with
pIOLs [18].
The cylinder did not change after the bilensectomy;
our outcomes agree with those reported in a previous
study [9].
In a previous study [19], as well as in this study, cataract
was the main cause for phakic IOL explantation. Anterior
subcapsular opacification is the most common type of
cataract after the implantation of a pIOL and it is pre-
sumed to be caused by the contact between the crystalline
lens and the pIOL, trauma during surgery, intermittent
trauma from accommodation, subclinical inflammation,
insufficient vaulting, lens malnutrition and crystalline lens
trauma from preoperative Nd:YAG laser peripheral iridot-
omy [6, 20]. The development of cataract with the latest
model of ICL (V4c) is less common than with older
models [7] due to the central hole that reduces the risk of
cataract formation. The ICL (Fig. 7) was the most
explanted PC pIOL, which is explained by the fact that it
is the most widely implanted PC pIOL [21].
The time between PC pIOL implantation and bilen-
sectomy differ depending on the pIOL model: the mean
time was 8.2 ± 3.3 years for the ICL, which corroborate
with the results from Meier et al. [9], but not with the
ones from Kamiya et al. [10] (3.6 years). We assume that
the difference in time was due to the ICL model, as
Kamiya et al. [10] explanted more V2 models, which had
a higher rate of cataract formation [22]. The mean time
between the IPCL implantation and bilensectomy was
short (0.4 years) compared to the other two PC pIOL
models. A study [23] reported cataract formation within
1 year of IPCL implantation in 2.9% of the eyes studied,
although only one eye required bilensectomy, with good
final visual outcome (CDVA 20/25).
The PRL has been phased out the market due to its
associated complications [5, 24]. It has been reported
that contact with the haptics of the PRL causes zonu-
lar weakening which results in the dislocation of the
pIOL [25]. Furthermore, patients with high axial my-
opia have weaker zonules due to the excessive
stretching of the zonular fibers [24], and both factors
might have contributed to the dislocation of the pIOL
in our patient.
We had one combined procedure of bilensectomy and
DSAEK secondary to endothelial cell loss; a study [26]
reported good visual outcomes and graft survival in eyes
undergoing this combined procedure. Endothelial cell
loss rate after PC pIOL implantation differs between
clinical studies [27–29]. It has been reported that there










ICL (n: 72) 20/175 20/40 0.00 20/50 20/25 0.00
IPCL (n: 7) 20/80 20/25 0.01 20/35 20/20 0.01
PRL (n: 8) 20/60 20/30 0.08 20/50 20/25 0.04
pIOL= phakic intraocular lens, UCVA= uncorrected distance visual acuity, CDVA= corrected distance visual acuity
Fig. 3 Histogram of postoperative CDVA and UCVA
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is no chronic loss of endothelial cells after the implant-
ation of a PC pIOL [30], because there is no direct con-
tact between the pIOL and the corneal endothelium. On
the other hand, an 8-year follow up study [31] reported
a mean percentage of endothelial cell loss of 6.2% after
the implantation of the ICL pIOL.
We did not observe a significant loss in ECC after
bilensectomy, so the procedure does not seem to signifi-
cantly damage the corneal endothelium.
High myopic eyes and young patients (< 50 years) have
a higher risk of RD [31–33] after cataract surgery. There
was one case of RD in our study. This finding does not
agree with previous studies [9–11] where no cases of RD
were reported after PC pIOL bilensectomy. This might
be secondary to our higher number of patients and the
fact that our patients were younger (mean age of 44.4
years) than the patients in other studies [9, 10] (mean
age of 47.2 and 50.39 years).
One eye required pupilloplasty due to a hyporeactive
mydriatic pupil. Although pupillary defects are not com-
mon after the implantation of PC pIOLs, cases of fixed
mydriatics pupils secondary to Urrets-Zavalia syndrome
have been reported [34, 35]. Probably, pupil-related visual
problems are an under reported feature in PC pIOL
implantation.
Two eyes required a combined procedure with trabe-
culectomy: these eyes had pigment over the trabecular
meshwork and high intraocular pressure. Sanchez-
Galeana et al. [36] reported a case of intractable pigmen-
tary glaucoma that required pIOL explantation and tra-
beculectomy in order to control the IOP. Pigment
dispersion is related to chronic chafing by the pIOL.
Fig. 4 Histogram of lines of difference between postoperative UDVA and CDVA
Fig. 5 Postoperative spherical equivalent refraction
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One of the main limitations of this study is that we
could not get the vault measurement of the PC pIOL be-
fore the bilensectomy surgery to ascertain its potential
correlation with the cataract development.
To the best of our knowledge, this is a study with the
largest number of eyes and the longest follow up time
(mean 14.5 months) after PC pIOL bilensectomy, and
the only one that reports the outcomes of three different
types of PC pIOLs.
Conclusions
In conclusion, the main cause for bilensectomy following
PC-pIOL implantation was cataract development in our
sample, and the visual and refractive outcomes were ac-
ceptable. It was a safe procedure in which we did not
observe significant endothelial cell loss, and with few
intra or postoperative complication rates. RD is a serious
postoperative complication that should be monitored in
young patients.
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